PEDRO
PÉREZ SEGURA
Profesor asociado de Ciencias de la Salud
![Foto de PEDRO](/img/nophoto.png)
![Foto de Hospital Universitari Germans Trias i Pujol](/img/noimage_org.png)
Hospital Universitari Germans Trias i Pujol
Barcelona, EspañaPublications en collaboration avec des chercheurs de Hospital Universitari Germans Trias i Pujol (15)
2020
-
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
Neuro-oncology, Vol. 22, Núm. 12, pp. 1851-1861
2018
-
Correction to: SEOM clinical guidelines for anaplastic gliomas (2017) (Clinical and Translational Oncology, (2018), 20, 1, (16-21), 10.1007/s12094-017-1762-7)
Clinical and Translational Oncology
-
Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1529-1537
-
SEOM clinical guidelines for anaplastic gliomas (2017)
Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 16-21
2017
-
FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence
Clinical and Translational Oncology, Vol. 19, Núm. 8, pp. 997-1009
2016
-
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial
Journal of Neuro-Oncology, Vol. 127, Núm. 3, pp. 569-579
2015
-
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
Clinical and Translational Oncology, Vol. 17, Núm. 9, pp. 743-750
-
Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 264-273
2014
-
Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry
Journal of Neuro-Oncology, Vol. 116, Núm. 2, pp. 413-419
-
Erratum: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry [J Neurooncol, 116, (2014), 413-419, DOI 10.1007/s11060-013-1316-y]
Journal of Neuro-Oncology
-
Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain
Clinical and Translational Oncology, Vol. 16, Núm. 3, pp. 273-279
2012
-
Guidelines for biomarker testing in colorectal carcinoma (CRC): A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 14, Núm. 10, pp. 726-739
-
Recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica
Revista Espanola de Patologia
-
SEOM guideline for the treatment of malignant glioma
Clinical and Translational Oncology, Vol. 14, Núm. 7, pp. 545-550
2010
-
Extended-schedule dose-dense temozolomide in refractory gliomas
Journal of Neuro-Oncology, Vol. 96, Núm. 3, pp. 417-422